FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028550899> ?p ?o ?g. }

• W3028550899 endingPage "523" @default.
• W3028550899 startingPage "511" @default.
• W3028550899 abstract "People with type 1 diabetes who use continuous subcutaneous insulin infusion (CSII, or insulin pump therapy) often remove their pump before extended periods of exercise, but this approach might result in reduced glycaemic control and increased risk of hyperglycaemia and ketogenesis. We aimed to assess the efficacy and safety of a hybrid approach, in which basal insulin delivery was divided between CSII and a daily injection of insulin degludec.In this single-centre, open-label, proof-of-concept, randomised crossover trial done at the LMC Diabetes & Endocrinology research centre, we recruited physically active and aerobically fit participants aged 18 years or older with type 1 diabetes who were using CSII. Participants were randomly assigned (1:1) by use of a computer-generated sequence to one of two sequences of either usual CSII, involving the continuation of the participant's usual CSII regimen, followed by crossover to hybrid CSII, in which the delivery of the participant's usual daily basal insulin dose was split (50% delivered by CSII and 50% delivered by a once-daily morning injection of 100 U/mL insulin degludec), or the opposite sequence (ie, hybrid CSII followed by crossover to usual CSII). Treatment was not masked to the investigators or participants. For each intervention, participants completed a moderate-intensity and a high-intensity in-clinic exercise session in the first week, followed by four high-intensity and two moderate-intensity home-based exercise sessions in the subsequent 3 weeks. Insulin pumps were suspended or disconnected 60 min before exercise and reconnected immediately after exercise during both treatment regimens. The coprimary outcomes were: (1) time spent in the target control range of 4·0-10·0 mmol/L blood glucose after high-intensity exercise, and (2) time spent in target control range of 4·0-10·0 mmol/L blood glucose after moderate-intensity exercise, measured by continuous glucose monitoring in the 6-h period from the start of the high-intensity and moderate-intensity in-clinic exercise sessions. Outcomes were assessed in a modified intention-to-treat population that included all participants who started both intervention phases and completed all of the in-clinic exercise visits. This trial is registered with ClinicalTrials.gov, NCT03838783, and is complete.Between May 15, 2018, and March 5, 2019, we assessed 43 patients for eligibility, of whom 31 were randomly assigned to receive the usual CSII regimen (n=14) or hybrid CSII regimen (n=17) in the first phase (before crossover). The analysis population consisted of 24 participants who completed both study phases. Compared with the usual CSII regimen, participants on the hybrid CSII regimen had a significantly longer time in blood glucose range of 4-10 mmol/L during the 6-h period from the start of both moderate-intensity (mean difference 86 min [95% CI 61-147], p=0·005; percentage time in range 64% [SD 35] vs 40% [35]) and high-intensity in-clinic exercise session (60 min [11-109], p=0·01; 66% [32] vs 50% [27]). Participants on the hybrid CSII regimen also showed a higher time in blood glucose range of 4-10 mmol/L during home-based exercise sessions (mean difference 23 min [95% CI -1 to 46], p=0·055), with significantly lower time spent in hyperglycaemia than participants on the usual CSII regimen (mean difference 25 min [2-48], p=0·04). These exploratory outcomes also showed no significant difference in the amount of time spent in hypoglycaemia, nor the number of hypoglycaemic events, between the two interventions. There were three study-related adverse events reported with the usual CSII regimen (two hypotension events and one nausea event) and four with the hybrid CSII regimen (two hypotension events and two nausea events).A hybrid regimen of injected insulin degludec and CSII (with pump removal during exercise) appears to be safe and effective in adults with type 1 diabetes who exercise regularly. This approach could offer improved glycaemic control immediately after exercise and should be further assessed in a larger-scale randomised trial.Novo Nordisk." @default.
• W3028550899 created "2020-05-29" @default.
• W3028550899 creator A5000001589 @default.
• W3028550899 creator A5002976448 @default.
• W3028550899 creator A5071109746 @default.
• W3028550899 creator A5075661431 @default.
• W3028550899 creator A5078369032 @default.
• W3028550899 date "2020-06-01" @default.
• W3028550899 modified "2023-09-27" @default.
• W3028550899 title "Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial" @default.
• W3028550899 cites W1492041642 @default.
• W3028550899 cites W1923792191 @default.
• W3028550899 cites W1980143207 @default.
• W3028550899 cites W1995536824 @default.
• W3028550899 cites W2004008756 @default.
• W3028550899 cites W2020714933 @default.
• W3028550899 cites W2035328959 @default.
• W3028550899 cites W2055179027 @default.
• W3028550899 cites W2075526594 @default.
• W3028550899 cites W2087338218 @default.
• W3028550899 cites W2125676337 @default.
• W3028550899 cites W2135944584 @default.
• W3028550899 cites W2162727613 @default.
• W3028550899 cites W2169640436 @default.
• W3028550899 cites W2361224378 @default.
• W3028550899 cites W2403070057 @default.
• W3028550899 cites W2413613496 @default.
• W3028550899 cites W2516779908 @default.
• W3028550899 cites W2536270858 @default.
• W3028550899 cites W2580463185 @default.
• W3028550899 cites W2728434455 @default.
• W3028550899 cites W2886769875 @default.
• W3028550899 cites W2888701093 @default.
• W3028550899 cites W2888955158 @default.
• W3028550899 cites W2891494773 @default.
• W3028550899 cites W2910634012 @default.
• W3028550899 cites W2916165156 @default.
• W3028550899 doi "https://doi.org/10.1016/s2213-8587(20)30114-5" @default.
• W3028550899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32445738" @default.
• W3028550899 hasPublicationYear "2020" @default.
• W3028550899 type Work @default.
• W3028550899 sameAs 3028550899 @default.
• W3028550899 citedByCount "13" @default.
• W3028550899 countsByYear W30285508992020 @default.
• W3028550899 countsByYear W30285508992021 @default.
• W3028550899 countsByYear W30285508992022 @default.
• W3028550899 countsByYear W30285508992023 @default.
• W3028550899 crossrefType "journal-article" @default.
• W3028550899 hasAuthorship W3028550899A5000001589 @default.
• W3028550899 hasAuthorship W3028550899A5002976448 @default.
• W3028550899 hasAuthorship W3028550899A5071109746 @default.
• W3028550899 hasAuthorship W3028550899A5075661431 @default.
• W3028550899 hasAuthorship W3028550899A5078369032 @default.
• W3028550899 hasConcept C126322002 @default.
• W3028550899 hasConcept C134018914 @default.
• W3028550899 hasConcept C142724271 @default.
• W3028550899 hasConcept C1862650 @default.
• W3028550899 hasConcept C204787440 @default.
• W3028550899 hasConcept C27081682 @default.
• W3028550899 hasConcept C2775927303 @default.
• W3028550899 hasConcept C2777180221 @default.
• W3028550899 hasConcept C2779306644 @default.
• W3028550899 hasConcept C2779794567 @default.
• W3028550899 hasConcept C2779920387 @default.
• W3028550899 hasConcept C2780668416 @default.
• W3028550899 hasConcept C2781232474 @default.
• W3028550899 hasConcept C2781413609 @default.
• W3028550899 hasConcept C555293320 @default.
• W3028550899 hasConcept C71924100 @default.
• W3028550899 hasConcept C87813604 @default.
• W3028550899 hasConceptScore W3028550899C126322002 @default.
• W3028550899 hasConceptScore W3028550899C134018914 @default.
• W3028550899 hasConceptScore W3028550899C142724271 @default.
• W3028550899 hasConceptScore W3028550899C1862650 @default.
• W3028550899 hasConceptScore W3028550899C204787440 @default.
• W3028550899 hasConceptScore W3028550899C27081682 @default.
• W3028550899 hasConceptScore W3028550899C2775927303 @default.
• W3028550899 hasConceptScore W3028550899C2777180221 @default.
• W3028550899 hasConceptScore W3028550899C2779306644 @default.
• W3028550899 hasConceptScore W3028550899C2779794567 @default.
• W3028550899 hasConceptScore W3028550899C2779920387 @default.
• W3028550899 hasConceptScore W3028550899C2780668416 @default.
• W3028550899 hasConceptScore W3028550899C2781232474 @default.
• W3028550899 hasConceptScore W3028550899C2781413609 @default.
• W3028550899 hasConceptScore W3028550899C555293320 @default.
• W3028550899 hasConceptScore W3028550899C71924100 @default.
• W3028550899 hasConceptScore W3028550899C87813604 @default.
• W3028550899 hasIssue "6" @default.
• W3028550899 hasLocation W30285508991 @default.
• W3028550899 hasLocation W30285508992 @default.
• W3028550899 hasOpenAccess W3028550899 @default.
• W3028550899 hasPrimaryLocation W30285508991 @default.
• W3028550899 hasRelatedWork W2045993936 @default.
• W3028550899 hasRelatedWork W2055794815 @default.
• W3028550899 hasRelatedWork W2057262151 @default.
• W3028550899 hasRelatedWork W2057434408 @default.
• W3028550899 hasRelatedWork W2076754594 @default.
• W3028550899 hasRelatedWork W2081101301 @default.

• next